Key Drivers
- Very high liquidity
- Zero revenue
- High cash burn
AIAI Summary
MLYS has shifted from long‑horizon R&D optionality to an event‑driven, binary investment where FDA approval of lorundrostat (PDUFA 2026‑12‑22) would unlock material near‑term commercial upside but failure, restrictive labeling, or safety‑driven trials would sharply compress value and likely force dilution. Investors should size positions around the PDUFA outcome and upcoming partnering/label signals — trim or hedge pre‑decision given the single‑outcome risk, and look to add only on clear approval, favorable label language, or a de‑risking commercialization partner announcement.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high liquidity
- •Zero revenue
- •High cash burn
MLYS is extremely cash- and investment-rich with negligible leverage but faces zero revenue, large operating losses (~$170.6M), deep negative free cash flow (~-$142.4M) and continued quarterly cash burn, while the market prices it well above tangible book.
Price Behavior
Key Price Behavior Insights:
- •Below last-month average
- •Support testing
- •Gap-down supply
MLYS is in a short-term downtrend—last month avg ≈ $27.29 vs last trade $24.05 (~12% below), sitting on support near $23.28–$24.05 with resistance at $28–$30 and a recent gap down signaling rallies are likely to meet supply until price reclaims the last-month average or breaks below support.
Recent gap down from the $28–$30 area into the current range increases likelihood that rallies will hit supply
Sentiment & News
Key News Insights:
- •FDA NDA acceptance
- •BP efficacy signal
- •Divergent ownership
Mineralys secured FDA NDA acceptance for lorundrostat with a PDUFA date, reported mixed Phase 2 OSA efficacy but BP benefit and good tolerability, and saw divergent institutional trading alongside routine corporate updates.
FDA acceptance materially de‑risks lorundrostat's regulatory path and could drive upside if the PDUFA outcome and commercial prospects align, though mixed Phase 2 efficacy and shifting institutional positions add near‑term uncertainty
Similar Companies in Healthcare
Other companies in the same sector with AI ratings